Valuation: Inotiv, Inc.

Market Cap 387K 338K 319K 290K 542K 37.16M 545K 3.82M 1.47M 18.89M 1.45M 1.42M 60.79M P/E 2024
-0.41x
P/E 2025 -0.69x
Enterprise Value 438M 382M 361M 327M 613M 42.02B 616M 4.32B 1.67B 21.36B 1.65B 1.61B 68.74B EV / Sales 2024
0.95x
EV / Sales 2025 0.95x
Free-Float
93.37%
Yield 2024 *
-
Yield 2025 -
1 day-26.00%
3 months-23.45%
6 months-97.05%
Current year-98.03%
Current year 0.01
Extreme 0.007
0.65
1 year 0.01
Extreme 0.007
1.62
3 years 0.01
Extreme 0.007
11.42
5 years 0.01
Extreme 0.007
60.66
10 years 0.01
Extreme 0.007
60.66
Manager TitleAgeSince
Chief Executive Officer 67 12/01/2019
Director of Finance/CFO 61 06/03/2020
Chief Operating Officer 60 15/02/2021
Date Insider Type Main position Quantity % Market Cap. Importance
19/7/26 Others

Chief Executive Officer

-1,361,215 3.9017%
19/7/26 Others

Director

-729,626 2.0913%
19/7/26 Others

Chief Financial Officer

-139,616 0.4002%
Change 5-day change 1-year change 3-year change Capi.($)
-26.00%-.--%-99.23%-99.66% 387K
+0.11%+2.71%+0.33%+28.59% 46.28B
-1.12%+1.78%+40.07%+27.26% 43.85B
-3.04%-6.29%+322.27%+517.36% 40.93B
-0.74%+1.25%+2.32%+67.94% 39.9B
-0.50%+0.67%+11.79%+40.51% 29.5B
-0.46%+4.22%+21.99%+124.21% 17.09B
-0.97%-10.17% - - 15.55B
-0.57%+8.12%+22.15%+38.93% 15.22B
-3.14%+31.91%-10.60% - 14.05B
Average -3.49%-0.45%+34.57%+93.14% 26.24B
Weighted average by Cap. -1.02%+1.87%+64.69%+130.23%

Financials

2024 2025
Net sales 491M 428M 404M 367M 687M 47.09B 690M 4.84B 1.87B 23.94B 1.84B 1.8B 77.03B 513M 447M 422M 384M 719M 49.23B 722M 5.06B 1.95B 25.03B 1.93B 1.88B 80.53B
Net income -108M -94.56M -89.29M -81.08M -152M -10.41B -153M -1.07B -413M -5.29B -407M -398M -17.02B -68.62M -59.84M -56.5M -51.31M -96.13M -6.58B -96.53M -677M -261M -3.35B -258M -252M -10.77B
Net Debt 424M 369M 349M 317M 594M 40.66B 596M 4.18B 1.61B 20.67B 1.59B 1.56B 66.51B 438M 382M 360M 327M 613M 41.98B 615M 4.32B 1.67B 21.35B 1.64B 1.61B 68.68B
Logo Inotiv, Inc.
Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
Employees
1,996
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. NOTV Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!